Stresam (etifoxine) regularly appears in research linking anxiolytics and weight variation. Prescribed for the psychological and somatic manifestations of anxiety, this medication raises many questions about a potential slimming effect. The available clinical data, including recent European re-evaluations, do not support this hypothesis.
Etifoxine and body weight: what pharmacovigilance data say
The European re-evaluation of etifoxine conducted by the CHMP of the EMA, concluded in January 2022, reviewed all pharmacovigilance signals reported since the marketing of Stresam. Neither weight loss nor weight gain are among the significant adverse effects identified during this process.
Recommended read : Discover the ideal platform for male and female health professionals
This point deserves to be emphasized, as most popular articles mention a possible link between Stresam and weight loss without citing clinical sources. Field reports vary on this point: some patients report a change in appetite while on treatment, while others observe no change. These isolated testimonies do not constitute pharmacological evidence.
An article detailing the dosage of Stresam and weight loss reminds us that the confusion often arises from an indirect mechanism: the reduction of anxiety can alter eating behaviors (compulsive snacking, stress-related loss of appetite), which sometimes leads to weight variation without the medication acting on metabolism.
Further reading : How to Determine the Ideal Weight for a Woman Who is 1.62m: Tips and Practical Advice
Stresam dosage and treatment duration: the framework set by the EMA in 2022
The European re-evaluation has redefined the scope of etifoxine use. Stresam is now reserved for mild to moderate anxiety in adults, for short periods of a few weeks, with regular re-evaluation by the prescribing physician.
The usual dosage remains that mentioned in the product characteristics summary. However, the duration restriction is a notable change from previous practices. Before 2022, some patients extended their treatment over several months, sometimes without close medical follow-up.
Why the short duration matters for weight
Over a few weeks of treatment, direct metabolic changes remain unlikely for most non-benzodiazepine anxiolytic molecules. Etifoxine does not act on the same receptors as benzodiazepines, which explains a different side effect profile, notably the absence of documented physical dependence.
If weight loss occurs during treatment with Stresam, it is more likely related to the reduction of anxiety disorders themselves (lower cortisol, return to regular eating) than to a pharmacological effect specific to the molecule.
Side effects of Stresam: alerts not to be underestimated
Public information sheets prior to 2022 generally list drowsiness and digestive disorders. The strengthened warnings from the EMA procedure go further and deserve special attention.
- Hepatotoxicity: cases of liver damage have been reported in pharmacovigilance, warranting monitoring of liver function at the start of treatment.
- Severe skin reactions: severe rashes that may require immediate discontinuation of treatment and emergency consultation.
- Drowsiness at the beginning of treatment, with a potential impact on driving and alertness at work.
These effects remain infrequent in the available data, but their potential severity justifies the close clinical monitoring recommended in the first weeks. Any rash or yellowing of the skin requires stopping Stresam and immediate consultation.
Interaction with alcohol and other substances
The combination of Stresam with alcohol is not recommended: the sedative effect may be amplified. This precaution, common to almost all anxiolytics, takes on additional significance for patients who consume alcohol to manage their anxiety, a common pattern in untreated anxiety disorders.
Stresam, benzodiazepines, and antidepressants: actual positioning in the therapeutic arsenal
Etifoxine stands out from benzodiazepines (Xanax, Lexomil) on a regularly highlighted point: Stresam is not believed to cause physical dependence according to available data. This profile makes it a first-line option for circumscribed anxious episodes.
However, Stresam is not an antidepressant. It does not act on serotonin like selective serotonin reuptake inhibitors (SSRIs), and does not treat associated depressive disorders. In patients with comorbid anxiety-depression, the physician will likely steer towards combined treatment or another therapeutic class.
The non-reimbursement of Stresam by Health Insurance, a direct consequence of its medical service deemed insufficient by HAS, constitutes a concrete barrier for some patients. This economic parameter can influence treatment adherence and, indirectly, the long-term management of anxiety.
The question of the link between Stresam and weight loss is based on individual testimonies, not on clinical evidence. The data from the EMA re-evaluation of 2022 mention no significant weight effect. Any weight change during anxiolytic treatment warrants a discussion with the prescribing physician to identify the real cause, whether behavioral, hormonal, or related to another concomitant treatment.